Clinical trials: Pituitary Cancer
Prolactinoma, Macroprolactinoma
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and…
- Trial name
- OEMacroPrL (NCT07268183)
- Testing
- Standardized questionnaire
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Ovarian Neoplasms
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms
This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign…
- Trial name
- NCT00160472
- Testing
- removal of ovarian vessels
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- United States Department of Defense
Acromegaly, GEP-NET
A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning…
- Trial name
- OXTEND-01 (NCT05364944)
- Testing
- Debio 4126, Sandostatin LAR, Somatuline ATG
- Where
- 14 sites in Denmark, France and 6 more
- Volunteers
- 19 people
- Sponsor
- Debiopharm International SA
Pituitary Adenoma
Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT
This is a prospective case-control study to compare the usefulness of 18F-FDG PET/MRI with that of 18F-FDG PET/CT in detection of functioning pituitary microadenomas.A single dose of 370 Mega-Becquerel (MBq) 18F-FDG will be…
- Trial name
- NCT03404414
- Testing
- 18F-FDG
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Long Term, Hypopituitarism
Long-Term Outcomes of Hypopituitarism Following Gamma Knife Radiosurgery for Pituitary Adenomas
This study aims to assess long-term outcomes of hypopituitarism following gamma knife radiosurgery (GKRS) for pituitary adenomas.
- Conditions
- Long Term, Hypopituitarism, Gamma Knife Radiosurgery, Pituitary Adenomas
- Trial name
- NCT07015645
- Testing
- Gamma Knife Radiosurgery
- Where
- Egypt
- Volunteers
- 137 people
- Sponsor
- Al-Azhar University
Pituitary Adenoma, Pituitary Tumor
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
This project is the first comprehensive prospective study of clinically non-functioning pituitary adenomas (CNFAs). Two groups of subjects will be studied: Group I will consist of 100 patients with clinically non-functioning…
- Trial name
- PAPS (NCT01556230)
- Testing
- Surgical intervention for CNFA, Radiotherapy for CNFA
- Where
- United States
- Volunteers
- 292 people
- Sponsor
- Columbia University
Prolactinoma, Prolactin Excess
Safety and Potency of a High Cabergoline Dosage in Microprolactinomas
This will be a multicenter, prospective, randomized, open-label trial with women harboring microprolactinomas and treatment naïve.
- Trial name
- SPARAGMOS (NCT07463235)
- Testing
- Cabergoline
- Where
- 16 sites in Brazil
- Volunteers
- 70 people
- Sponsor
- University of Sao Paulo General Hospital
Acromegaly
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
- Trial name
- PAOLA (NCT01137682)
- Testing
- Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
- Where
- 60 sites in United States, Argentina and 16 more
- Volunteers
- 198 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Adenoma
Endocrine Outcome of Surgery for Pituitary Adenoma
Prospective and randomized compare between microsurgical and endoscopic transsphenoidal MRI assisted resection of pituitary adenomas.
- Trial name
- NCT03515603
- Testing
- Endoscopic resection, Microsurgical resection
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- University of Ulm
Acromegaly, Pituitary Neoplasm
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
The purpose of this study is to compare the efficacy of Sandostatin LAR® (Registered Trademark) Depot to transsphenoidal surgery in previously untreated acromegalic patients with macroadenomas.
- Trial name
- NCT00001860
- Testing
- Sandostatin LAR Depot versus transsphenoidal surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pituitary Tumor, Optic Chiasm Disorder
Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma
Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression.
- Trial name
- RetroADEN (NCT03363126)
- Testing
- Endonasal transsphenoidal pituitary tumor removal
- Volunteers
- 88 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Pituitary Disease
China Pituitary Disease Registry (CAPASITY)
Epidemiologic studies have revealed a tremendous increase in the prevalence of pituitary disease and related mortality worldwide.
- Trial name
- NCT04713293
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pituitary Neoplasms, Prolactinoma
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
The purpose of this research study is to determine the utility of educational materials designed to inform patients of their pituitary condition, in an effort to assist the patients, families, and staff deal with pituitary…
- Conditions
- Pituitary Neoplasms, Prolactinoma, ACTH-Secreting Pituitary Adenoma, Gigantism
- Trial name
- NCT01775332
- Testing
- Educational Intervention
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Pituitary Adenoma
Multicentric Prospective Validation of the Zurich Pituitary Score
Predictive analytics for GTR, EOR and RV are useful in surgical decision-making, particularly whenever there is no unequivocal indication for surgery. Several factors have been shown to have a role in predicting GTR.
- Trial name
- NCT04076046
- Where
- 10 sites in United States, Austria and 4 more
- Volunteers
- 408 people
- Sponsor
- University of Zurich
Pituitary Tumor
Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
Investigators hypothesized that propofol dose for pituitary somatotroph patients might differ from nonfunctioning pituitary tumor, and investigators will evaluate a target controlled infusion (TCI) effect site concentration (Ce)…
- Trial name
- NCT03465423
- Testing
- Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Yonsei University
Acromegaly Due to Pituitary Adenoma, Hyperglycemia
Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic Diet
Rationale: Pasireotide is a second line medical treatment for acromegaly that can add value for patients with insufficient control of disease on 1st generation SRL, or 1st generation SRL + pegvisomant.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Hyperglycemia, Ketogenic Diet, Standard Care Control
- Trial name
- PasiAcroKeto (NCT07866846)
- Testing
- Ketogenic diet, Diabetes Medication
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Leiden University Medical Center
Neuroendocrine Tumors, Insulinoma
DOTATOC PET/CT for Imaging NET Patients
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called…
- Conditions
- Neuroendocrine Tumors, Insulinoma, Gastrinoma, Glucagonoma
- Trial name
- NCT03583528
- Testing
- 68Ga-DOTATOC PET/CT, 18F-FDG PET/CT
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- British Columbia Cancer Agency
Pituitary Neoplasm
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Background: Cushing s disease can be caused by a tumor of the pituitary gland, a small gland about the size of a pea located at the base of the brain.
- Trial name
- NCT01459237
- Testing
- Acthrel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Pituitary Adenoma
Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma
The images of patients with Pituitary adenoma were collected and analyzed based on the methods of radiomics.
- Trial name
- RIPA (NCT06234553)
- Testing
- surgery of pituitary adenomas
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing Tiantan Hospital